Zacks Investment Research lowered shares of Bio-Techne Corp (NASDAQ:TECH) from a hold rating to a sell rating in a report issued on Thursday morning.

According to Zacks, “Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota. “

Separately, Leerink Swann began coverage on Bio-Techne Corp in a report on Thursday, November 10th. They issued an outperform rating and a $122.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $121.00.

Shares of Bio-Techne Corp (NASDAQ:TECH) traded down 0.24% during midday trading on Thursday, hitting $101.77. The stock had a trading volume of 80,193 shares. Bio-Techne Corp has a 52-week low of $79.95 and a 52-week high of $117.42. The firm has a market cap of $3.80 billion, a price-to-earnings ratio of 38.86 and a beta of 0.71. The firm’s 50 day moving average price is $105.00 and its 200 day moving average price is $107.56.

Bio-Techne Corp (NASDAQ:TECH) last posted its quarterly earnings data on Monday, October 31st. The company reported $0.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.05. Bio-Techne Corp had a return on equity of 14.40% and a net margin of 18.96%. The company had revenue of $130.60 million for the quarter, compared to analysts’ expectations of $127.47 million. During the same period in the previous year, the firm posted $0.79 EPS. Bio-Techne Corp’s revenue was up 16.2% compared to the same quarter last year. On average, equities research analysts expect that Bio-Techne Corp will post $3.63 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Bio-Techne Corp (TECH) Lowered to “Sell” at Zacks Investment Research” was first posted by Daily Political and is the propert of of Daily Political. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright laws. The original version of this article can be viewed at http://www.dailypolitical.com/2017/01/13/bio-techne-corp-tech-lowered-to-sell-at-zacks-investment-research-2.html.

In other news, Director Karen A. Holbrook sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 29th. The stock was sold at an average price of $106.73, for a total transaction of $106,730.00. Following the transaction, the director now directly owns 1,973 shares in the company, valued at approximately $210,578.29. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. LS Investment Advisors LLC bought a new position in shares of Bio-Techne Corp during the second quarter valued at $103,000. World Asset Management Inc raised its stake in Bio-Techne Corp by 33.3% in the third quarter. World Asset Management Inc now owns 2,417 shares of the company’s stock valued at $265,000 after buying an additional 604 shares during the last quarter. Eaton Vance Management purchased a new stake in Bio-Techne Corp during the second quarter valued at approximately $283,000. Cantab Capital Partners LLP purchased a new stake in Bio-Techne Corp during the second quarter valued at approximately $620,000. Finally, Wasatch Advisors Inc. raised its stake in Bio-Techne Corp by 8.9% in the third quarter. Wasatch Advisors Inc. now owns 6,724 shares of the company’s stock valued at $736,000 after buying an additional 547 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Bio-Techne Corp Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

5 Day Chart for NASDAQ:TECH

Get a free copy of the Zacks research report on Bio-Techne Corp (TECH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.